戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 s, angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, aldosterone antagonists, and d
2                                              beta-adrenergic blockers, amiodarone, and sotalol are th
3 and medications for CVD treatment, including beta-adrenergic blockers and ACE inhibitors, potentially
4  glutamate could be reversibly suppressed by beta-adrenergic blockers and the order of inhibitory pot
5  be achieved using calcium-channel blockers, beta-adrenergic blockers, and class I or III antiarrhyth
6 ia photo- and bio-transformations, including beta-adrenergic blockers, antivirals, antibiotics, and p
7                                              beta-adrenergic blockers are still the most common medic
8 hibitors, angiotensin-receptor blockers, and beta-adrenergic blockers, are routinely used and are qui
9 ostone, alpha(2)-adrenergic agonists (AAAs), beta-adrenergic blockers (BABs), carbonic anhydrase inhi
10                 Initial treatment included a beta-adrenergic blocker (beta-blocker) alone in 24%, a c
11 hough initially thought to be harmful in HF, beta-adrenergic blockers (beta-blockers) have consistent
12 alone and in combination with propranolol (a beta-adrenergic blocker), both given systemically, to re
13                                 Nonselective beta-adrenergic blockers decrease portal pressure and pr
14 perimental conditions for SERS, we chose the beta-adrenergic blocker drug propranolol as the target a
15 laxis, angiotensin-receptor blockers (ARBs), beta-adrenergic blockers, epinephrine, and Kounis syndro
16                  Propranolol, a nonselective beta-adrenergic blocker, has been associated with reduce
17 angiotensin-converting enzyme inhibitors and beta-adrenergic blockers, has been shown to improve the
18     In addition, recent studies suggest that beta-adrenergic blockers have a beneficial effect on bot
19              Thiazide diuretics, niacin, and beta-adrenergic blockers impair glucose homeostasis.
20 ellular basis for the therapeutic actions of beta-adrenergic blockers in LQT1 and suggest that sodium
21 as observed with propranolol, a nonselective beta-adrenergic blocker, in pretreated animals such that
22                    Additionally, infusion of beta-adrenergic blockers into the amygdala blocks the me
23 ty in patients with CHF who are treated with beta-adrenergic blockers is currently unknown.
24 th previous reports that betaxolol and other beta-adrenergic blockers may exert its neuroprotective a
25  fight-or-flight stress response such as the beta-adrenergic blocker metoprolol and the beta-adrenerg
26              Use of antianginal medications (beta-adrenergic blockers, nitrates, and calcium-channel
27 ned the effectiveness of betaxolol and other beta-adrenergic blockers on glutamate-induced calcium si
28                  Carvedilol, a non-selective beta-adrenergic blocker originally designed to treat hig
29  at 6 months, 39% of patients were receiving beta-adrenergic blockers (preprocedure proportion, 43%;
30 aline, the centrally and peripherally acting beta-adrenergic blocker propranolol (4 or 10 mg/kg ip),
31 notypes were reversed by the addition of the beta-adrenergic blocker propranolol.
32 ects can be inhibited by the addition of the beta-adrenergic blocker propranolol.
33 d be greater after the administration of the beta-adrenergic blocker propranolol.
34 ick from a mammalian host, we administered a beta-adrenergic blocker, propranolol, to infected mice.
35      In patients with myocardial infarction, beta-adrenergic blockers reduce recurrent myocardial inf
36                          Prophylactic use of beta-adrenergic blockers reduces the incidence of postop
37                  Prophylactic treatment with beta-adrenergic blockers should be continued during the
38  or 10 mg/kg ip), or the peripherally acting beta-adrenergic blocker sotalol (4 or 10 mg/kg ip) immed
39 udies of left ventricular assist devices and beta-adrenergic blockers suggest that attenuation of pro
40     Propranolol is an approved non-selective beta-adrenergic blocker that is first line therapy for i
41                          Even at high doses, beta-adrenergic blockers, the first-line therapy, often
42                  Long-term administration of beta-adrenergic blockers to patients after myocardial in
43 vagotonic agents, alpha-adrenergic agonists, beta-adrenergic blockers, tricyclic or tetracyclic antid
44                                          The beta-adrenergic blocker was only effective when the drug
45                               Treatment with beta-adrenergic blockers was independently associated wi